10-QPeriod: Q1 FY2020

AbbVie Inc. Quarterly Report for Q1 Ended Mar 31, 2020

Filed May 8, 2020For Securities:ABBV

Summary

AbbVie Inc. reported strong financial results for the first quarter of 2020, demonstrating robust revenue growth and profitability. The company generated $8.6 billion in net revenues, an increase of 10.7% on a constant currency basis compared to the prior year, driven by the strong performance of its immunology portfolio, including HUMIRA, SKYRIZI, and RINVOQ, as well as growth in IMBRUVICA and VENCLEXTA. Diluted earnings per share reached $2.02, showcasing the company's effective operational management and strategic product positioning. The company is nearing the completion of its significant acquisition of Allergan plc, which is expected to close in May 2020. This transaction is poised to create a more diversified biopharmaceutical entity with leadership positions across multiple key therapeutic areas. Despite the ongoing global uncertainty surrounding the COVID-19 pandemic, AbbVie has maintained its focus on ensuring supply continuity for its medicines and has taken steps to support the global health response. The company's financial position remains strong, with significant cash flows from operations, providing flexibility for continued investment in its pipeline and returning capital to shareholders.

Financial Highlights

52 data points
Beta

Revenue

$8.62B

77.5% Gross Margin

Net Income

$3.01B

34.9% Net Margin

EPS (Diluted)

$2.02

Total Assets

$91.20B

Cash & Equivalents

$41.14B

Free Cash Flow

$3.69B

Financial Statements
Beta
Revenue$8.62B
Cost of Revenue$1.94B
Gross Profit$6.68B
SG&A Expenses$1.70B
Operating Expenses$5.02B
Operating Income$3.60B
Interest Expense$563.00M
Net Income$3.01B
EPS (Basic)$2.02
EPS (Diluted)$2.02
Shares Outstanding (Basic)1.48B
Shares Outstanding (Diluted)1.48B

Key Highlights

  • 1AbbVie reported a 10.7% increase in net revenues on a constant currency basis, reaching $8.6 billion for Q1 2020.
  • 2Diluted earnings per share (EPS) was $2.02, reflecting solid profitability.
  • 3The acquisition of Allergan plc was nearing completion, with expected closing in May 2020, pending regulatory approvals.
  • 4HUMIRA sales grew by 13.7% in the U.S. driven by market growth, and globally increased by 5.8%.
  • 5Newer immunology drugs SKYRIZI and RINVOQ contributed $300 million and $86 million in revenue, respectively.
  • 6IMBRUVICA and VENCLEXTA showed strong revenue growth of 20.6% and over 100%, respectively.
  • 7The company maintained a strong cash flow from operating activities, amounting to $3.8 billion.

Frequently Asked Questions

The primary driver of AbbVie's revenue growth was the strong performance of its immunology portfolio, particularly HUMIRA in the U.S., along with significant contributions from newer immunology drugs like SKYRIZI and RINVOQ. Growth in hematologic oncology products IMBRUVICA and VENCLEXTA also played a key role.

The acquisition of Allergan plc was in its final stages and was expected to close in May 2020. Regulatory approvals were obtained, including from the FTC and the Irish High Court, subject to certain divestitures.

While the impact on operations to date was not material, COVID-19 did result in an inventory stocking benefit of approximately $65 million for U.S. HUMIRA sales and other products, which is expected to reverse in the second quarter. AbbVie also made donations to support the global health response and continued to manage its supply chain to ensure uninterrupted medicine supply.

HUMIRA continues to show strength, particularly in the U.S., though international markets face biosimilar competition. SKYRIZI and RINVOQ are contributing significant new revenue streams following their recent approvals, indicating successful product launches and market penetration.